Assoc/Prof Kristen Radford

PhD

Principal Research Fellow - Cancer Immunotherapies Group

Projects

About me

A/Prof Kristen Radford is a Senior Research Fellow and NHMRC CDA Level 2 fellow. She completed her PhD in 1997 from the University of Newcastle, NSW and was awarded NSW Young Australian of the Year in 1998. She then undertook a postdoctoral position at Imperial Cancer Research Fund, London (now Cancer Research UK) developing new dendritic cell-based vaccine strategies for cancer immunotherapy. She joined Mater Research in 2001 and played a key role in obtaining the preclinical data that justified the first blood dendritic cell vaccine trial in prostate cancer that was completed in 2009. Her research interests are focussed on understanding basic dendritic cell biology in humans and applying this knowledge to develop more potent cancer vaccines.

Publications

Selected publications from the last 5 years:

Wilson, J., Cullup, H., Lourie, R., Sheng, Y., Palkova, A., Radford, K.J., Dickinson, A.M., Rice, A.M., Hart, D.N.J., Munster D.J. (2009) Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J. Exp. Med. 206(2):387-398.

Hardy M.Y., Kassianos, A.K., Vulink, A., Wilkinson, R., Jongbloed, S.L., Hart, D.N.J., Radford, K.J. (2009) “NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells”. Immunol Cell Biol. 87(8):606-14. 

Kassianos, A.J., Jongbloed, S.L., Hart, D.N.J., Radford, K.J. (2010) Isolation of human blood DC subtypes. Methods Mol Biol. 595:45-54.

Jongbloed, S.L., Kassianos, A.J., McDonald, K.M., Clark, G.J., Ju, X., Angel, C.E., Chen, C.J., Dunbar, P.R., Wadley, R.B., Vulink, A.J., Hart D.N.J., Radford. K.J. (2010) Human CD141+ (BDCA-3)+ Dendritic Cells Represent a Unique Myeloid Dendritic Cell Subset that Cross-presents Necrotic Cell Antigens. J. Exp. Med. Jun 7;207(6):1247-60.

Cullup H., Hsu, A.K.W., Kassianos, A.J., McDonald, K. Radford, K.J.,  Rice, A.M., (2011)  CD34+ cord blood DC induced anti-tumor lymphoid cells have efficacy in a murine xenograft model of human ALL. J Immunother. 34(4):362-71

Wilkinson R, Woods K, D'Rozario R, Prue R, Vari F, Hardy MY, Dong Y, Clements JA, Hart DN, Radford KJ. (2012) Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother. 61(2):169-79.

Kassianos AK, Hardy MY, Ju X, Vijayan D, Ding Y, Vulink AJE, McDonald KJ, Jongbloed SL, Wadley RB, Wells C, Hart DNJ, Radford KJ. (2012) Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli. Eur. J. Immunol. 42(6):1512-22. doi: 10.1002/eji.201142098.Radford KJ and Caminschi I. (2013) New Generation dendritic cell vaccines. Human Vaccines and Immunotherapeutics. 9 (2): 259-264.

Radford KJ, Shortman K and O’Keeffe M (2013). “Dendritic cells in Autoimmune Disease” in “The Autoimmune Diseases” 5th Edition, Elsevier. p175-186

Ding Y, Wilkinson A, Idris A, Fancke B, O’Keeffe M, Kahil D, Ju X, Lahoud MH, Caminschi I, Shortman K,  Rodwell R, Vuckovic S, Radford KJ. Flt3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ DC in vivo. J Immunol, 2014.192(4):1982-9..

Radford KJ, Tullett KM, Lahoud ML. “Dendritic cells and Cancer Immunotherapy” invited review. Current Opin Immunol. 2014. Apr; 27C:26-32

Tullett KM, Lahoud ML, Radford KJ. “Harnessing human dendritic cell subsets for immunotherapy” invited review. Front Immunol. 2014 May 22;5:239